1 – 10 of 321
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A : Data from the PedNet Study Group
2025) In Haemophilia(
- Contribution to journal › Article
- 2024
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
(
- Contribution to journal › Letter
-
Mark
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
(
- Contribution to journal › Article
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Recombinant FVIII replacement products for haemophilia A : An updated valuation by indirect comparison measuring area under the curve
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article